Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059

[1]  A. Tolcher,et al.  The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[2]  Julian Downward,et al.  RAS Interaction with PI3K: More Than Just Another Effector Pathway. , 2011, Genes & cancer.

[3]  Stephen L. Abrams,et al.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.

[4]  J. Engelman,et al.  The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Chambard,et al.  ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescence , 2010, The FEBS journal.

[6]  R. Duan,et al.  LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells. , 2009, Anticancer research.

[7]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[8]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[9]  S. Fulda,et al.  Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. , 2008, Cancer research.

[10]  H. Hua,et al.  Acetyl-keto-beta-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. , 2008, Cancer research.

[11]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[12]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[13]  P. M. Campbell,et al.  K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. , 2007, Cancer research.

[14]  B. Kaina,et al.  DNA damage-induced cell death by apoptosis. , 2006, Trends in molecular medicine.

[15]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[16]  M. Oren,et al.  The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis , 2005, Cell Death and Differentiation.

[17]  Rajesh Agarwal,et al.  Silibinin Up-regulates DNA-Protein Kinase-dependent p53 Activation to Enhance UVB-induced Apoptosis in Mouse Epithelial JB6 Cells* , 2005, Journal of Biological Chemistry.

[18]  S. Waxman,et al.  Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells , 2005, Molecular Cancer Therapeutics.

[19]  Ming-Shyue Lee,et al.  ERK inhibitor PD98059 enhances docetaxel‐induced apoptosis of androgen‐independent human prostate cancer cells , 2003, International journal of cancer.

[20]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[21]  T. Mak,et al.  ERK Activation Mediates Cell Cycle Arrest and Apoptosis after DNA Damage Independently of p53* , 2002, The Journal of Biological Chemistry.

[22]  M. Davis,et al.  Phosphoinositol 3 kinase inhibitor, LY294002 increases bcl-2 protein and inhibits okadaic acid-induced apoptosis in Bcl-2 expressing renal epithelial cells , 2002, Apoptosis.

[23]  G. Kroemer,et al.  Organelle-specific initiation of cell death pathways , 2001, Nature Cell Biology.

[24]  N. Holbrook,et al.  Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[25]  A. Almasan,et al.  Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells , 2000, Oncogene.

[26]  T. Cotter,et al.  Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals , 2000, Leukemia.

[27]  E. Lapetina,et al.  Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD 098059. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[29]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[30]  John G. Collard,et al.  Transfection by human oncogenes: Concomitant induction of tumorigenicity and tumor‐associated membrane alterations , 1985, International journal of cancer.

[31]  C. Marshall,et al.  Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1 , 1983, Nature.

[32]  Shashank K Singh,et al.  Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. , 2012, Bioorganic & medicinal chemistry letters.

[33]  S. C. Taneja,et al.  Boswellic acids: a group of medicinally important compounds. , 2009, Natural product reports.

[34]  H. Hua,et al.  Acetyl-Keto-B-Boswellic Acid Induces Apoptosis through a Death Receptor 5 – Mediated Pathway in Prostate Cancer Cells , 2008 .